Cadonilimab plus chemotherapy versus PD-1 inhibitor plus chemotherapy as first-line (1L) treatment for advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS <5: A propensity-matched, retrospective cohort study.

Journal of Clinical Oncology 2026 Open access

Read full text
Authors: Duqin Zhao, Zhongyue Wu, Yihui Huang, L Zhang, Nannan Zhang, Qing Wei, Jingjing Li, Jieer Ying, Qi Xu
DOI: 10.1200/jco.2026.44.2_suppl.407
Cited by: 0

Abstract

407 Background: Although PD-1 inhibitors plus chemotherapy have been established as 1L treatment for advanced G/GEJ cancer, the survival benefit remains limited in those with PD-L1 CPS

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Gastric Cancer Management and Outcomes Esophageal Cancer Research and Treatment

Publication details

Journal / source
Journal of Clinical Oncology
Volume
44
Issue
2_suppl
Pages
407–407
Publication date
10 January 2026
Language
EN